Frequencies for first 10,000 rows of drug8cl1 variable in nhamcsopd2004 dataset : drug class #1 for medication #8 | Freq. Percent Cum. ----------------------------------------+----------------------------------- anesthetics, local (injectable) | 4 0.04 0.04 anesthetics, general | 6 0.06 0.10 antidotes, specific | 2 0.02 0.12 antimicrobial agents, unspecified | 1 0.01 0.13 penicillins | 3 0.03 0.16 cephalosporins | 3 0.03 0.19 erythromycins/lincosamides/macrolides | 2 0.02 0.21 tetracyclines | 2 0.02 0.23 aminoglycosides | 4 0.04 0.27 sulfonamides and trimethoprim | 1 0.01 0.28 urinary tract antiseptics | 1 0.01 0.29 miscellaneous antibacterial agents | 3 0.03 0.32 quinolones/derivatives | 2 0.02 0.34 antifungals | 1 0.01 0.35 antiviral agents | 7 0.07 0.42 deficiency anemias | 11 0.11 0.53 anticoagulants/thrombolytics | 12 0.12 0.65 cardiac glycosides | 1 0.01 0.66 antiarrhythmic agents | 1 0.01 0.67 antianginal agents | 11 0.11 0.78 vascular disorders, cerebral/peripheral | 1 0.01 0.79 agents used to treat shock/hypotension | 2 0.02 0.81 antihypertensive agents | 24 0.24 1.05 diuretics | 19 0.19 1.24 relaxants/stimulants, urinary tract | 3 0.03 1.27 calcium channel blockers | 6 0.06 1.33 beta blockers | 7 0.07 1.40 alpha agonist/alpha blockers | 2 0.02 1.42 ace inhibitors | 14 0.14 1.56 sedatives and hypnotics | 15 0.15 1.71 antianxiety agents | 11 0.11 1.82 antipsychotic/antimanics | 8 0.08 1.90 antidepressants | 25 0.25 2.15 anorexiants/cns stimulants | 1 0.01 2.16 cns, miscellaneous | 1 0.01 2.17 alzheimer-type dementia | 1 0.01 2.18 antiemetics | 4 0.04 2.22 diagnostics, radiopaque & nonradioactiv | 1 0.01 2.23 disorders, acid/peptic | 32 0.32 2.55 antidiarrheals | 2 0.02 2.57 laxatives | 10 0.10 2.67 miscellaneous gastrointestinals | 1 0.01 2.68 antispasmodics/anticholinergics | 4 0.04 2.72 antacids | 1 0.01 2.73 hyperlipidemia | 29 0.29 3.02 vitamins/minerals | 15 0.15 3.17 nutrition, enteral/parenteral | 2 0.02 3.19 repl/regs of electrolytes/water balance | 9 0.09 3.28 calcium metabolism | 7 0.07 3.35 hematopoietic growth factor | 2 0.02 3.37 adrenal corticosteroids | 8 0.08 3.45 androgens/anabolic steroids | 1 0.01 3.46 estrogens/progestins | 2 0.02 3.48 blood glucose regulators | 14 0.14 3.62 thyroid/antithyroid | 8 0.08 3.70 contraceptives | 1 0.01 3.71 vaccines/antisera | 2 0.02 3.73 immunomodulators | 3 0.03 3.76 dermatologics, misc. | 3 0.03 3.79 topical steroids | 6 0.06 3.85 topical anti-infectives | 4 0.04 3.89 topical analgesics | 2 0.02 3.91 myasthenia gravis | 2 0.02 3.93 skeletal muscle hyperactivity | 5 0.05 3.98 anticonvulsants | 14 0.14 4.12 antimetabolites | 1 0.01 4.13 dna damaging drugs | 5 0.05 4.18 glaucoma | 2 0.02 4.20 ocular anti-infective/anti-inflammatory | 1 0.01 4.21 miscellaneous ophthalmics | 1 0.01 4.22 vertigo/motion sickness/vomiting | 6 0.06 4.28 analgesics, narcotic | 33 0.33 4.61 analgesics, non-narcotic | 22 0.22 4.83 antimigraine/other headaches | 1 0.01 4.84 antiarthritics | 8 0.08 4.92 antigout | 3 0.03 4.95 nsaid | 9 0.09 5.04 antiprotozoals | 2 0.02 5.06 antiasthmatics/bronchodilators | 24 0.24 5.30 antitussives/expectorants/mucolytics | 3 0.03 5.33 antihistamines | 13 0.13 5.46 corticosteroid-inhalation/nasal | 6 0.06 5.52 unclassified | 11 0.11 5.63 homeopathic products | 4 0.04 5.67 . | 9,433 94.33 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 28 Mar 2016